New triple therapy shows promise for hard-to-treat bile duct cancer
NCT ID NCT06178445
First seen Apr 17, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This study tests a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive bile duct or gallbladder cancer that cannot be removed by surgery. The goal is to see how well this triple therapy shrinks tumors. The trial includes 24 adults and is currently active but not recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Universitätsmedizin
Berlin, Germany
-
Hämatologisch-Onkologische Praxis Eppendorf (HOPE)
Hamburg, Germany
-
Krankenhaus Nordwest (KHNW)
Frankfurt, Germany
-
LMU München
München, Germany
-
Medizinische Hochschule Hannover
Hanover, Germany
-
Universitätsklinikum Augsburg
Augsburg, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
-
Universitätsklinikum Göttingen
Göttingen, Germany
Conditions
Explore the condition pages connected to this study.